Could Pfizer's COVID Pill Be Even Bigger Than Its Vaccine?
Pfizer (NYSE: PFE) has won the title of leader when it comes to coronavirus vaccine prevention. The company recently said it holds 74% of the U.S. vaccine market and 80% of the European market. That's great news. But things are getting even better. Now, Pfizer may be about to claim leadership in another blockbuster area: coronavirus treatment.
The big pharma company last week released results of a phase 2/3 trial of its investigational COVID-19 pill. Data were so strong that an independent monitoring committee recommended Pfizer stop enrolling patients in the trial -- and seek regulatory authorization. Moving forward, many of us have one big question. Could a Pfizer coronavirus pill be even bigger than the company's vaccine?
Image source: Getty Images.
Source Fool.com
